Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $18.0 million.

  • Gyre Therapeutics' Gains from Investment Securities fell 270.31% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 million, marking a year-over-year decrease of 270.31%. This contributed to the annual value of $18.1 million for FY2024, which is 110.87% down from last year.
  • Per Gyre Therapeutics' latest filing, its Gains from Investment Securities stood at $18.0 million for Q3 2025, which was down 270.31% from -$212000.0 recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Gains from Investment Securities high stood at $18.5 million for Q3 2024, and its period low was -$4.3 million during Q1 2024.
  • For the 5-year period, Gyre Therapeutics' Gains from Investment Securities averaged around $6.3 million, with its median value being $3.1 million (2021).
  • As far as peak fluctuations go, Gyre Therapeutics' Gains from Investment Securities skyrocketed by 55435.34% in 2022, and later crashed by 7724.94% in 2023.
  • Gyre Therapeutics' Gains from Investment Securities (Quarter) stood at $2.6 million in 2021, then surged by 554.35% to $17.0 million in 2022, then crashed by 77.25% to $3.9 million in 2023, then tumbled by 52.45% to $1.8 million in 2024, then surged by 879.07% to $18.0 million in 2025.
  • Its Gains from Investment Securities stands at $18.0 million for Q3 2025, versus -$212000.0 for Q2 2025 and $17.8 million for Q1 2025.